INNOVIVA INC (INVA)
Health Care · Specialty Pharmaceuticals · NASDAQ
Innoviva is a diversified pharmaceutical holding company managing a portfolio of respiratory royalty assets and specialty medicine operations.
What INNOVIVA INC does
Innoviva is a holding company with a diversified portfolio of assets, including royalty interests in respiratory pharmaceutical products and a segment focused on the development and commercialization of infectious disease and other specialty medicines. The company actively manages its investments through various equity interests and direct operational holdings in pharmaceutical products.
Themes: respiratory health, infectious disease treatment, biopharmaceutical royalties, biotech investment holding
Fundamentals
- Price$21.28 as of 2026-10-20 close
- Market cap$1.5B as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return+23.6% 2025-10-20 close $17.21 → 2026-10-20 close $21.28
- P/E4.94 as of 2026-10-20; earnings are mostly non-operating: 61% of trailing pre-tax income, to 2026-06-30
- Net margin+65.9% FY2025, SEC XBRL
- Gross margin+74.8% FY2025, SEC XBRL
- ROE+23.1% FY2025, SEC XBRL
- ROIC+15.8% NOPAT / (debt + equity - cash), average capital — 10-K FY2025 (year ended 2025-12-31)
- Debt / equity0.21 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+14.7% FY2025, SEC XBRL
- Revenue CAGR (3y)+7.5% SEC XBRL
- Beta0.14 as of 2026-09-02
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How INVA compares in its sector
- price-to-earnings ratiobottom 10% 181 covered Health Care peers, as of 2026-10-20
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-02
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-02
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-02
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which INVA reported a dividend payment is FY2019, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2019 ratio would not describe INVA today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2019) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $120M | $91M | $51M | -$83M | -$1.14 | $52M† | $429000† |
| Q1 FY2026 2026-03-31 | $98M | $76M | $38M | $187M | $2.22 | $35M | $492000 |
| Q4 FY2025 2025-12-31 | $115M† | $76M† | $39M† | $164M† | $1.95† | $55M† | $10000† |
| Q3 FY2025 2025-09-30 | $108M | $76M | $35M | $90M | $1.08 | $50M† | $1M† |
| Q2 FY2025 2025-06-30 | $100M | $83M | $49M | $64M | $0.77 | $44M† | $0† |
| Q1 FY2025 2025-03-31 | $89M | $73M | $41M | -$47M | -$0.74 | $49M | $0 |
| Q4 FY2024 2024-12-31 | $92M† | $78M† | $43M† | $20M† | $0.31† | $59M† | $0† |
| Q3 FY2024 2024-09-30 | $90M | $73M | $43M | $1M | $0.02 | $49M† | $270000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$570M
- Total debt$258M borrowings only; leases excluded
- Net debt-$312M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How INNOVIVA INC looks technically
INNOVIVA INC (INVA) is trading 2.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 39 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day high about 7 trading days ago. It is 15.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 2.3% below its 200-day average, the long-term trend line — a long-term downtrend | -2.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $20.99 | $20.99 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $21.79 | $21.79 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 21.45. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 39 trading days ago — a "death cross", a bearish long-term signal | 39 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 11.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 54.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($20.45 to $21.76) — its "stochastic" reading is 63 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 63.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $25.14 | $25.14 |
|---|---|---|
| From the 52-week high | it is 15.4% below its 52-week high (its highest price of the past year) | -15.4% |
| Above the 52-week low | it is 28.8% above its 52-week low (its lowest price of the past year) | +28.8% |
| Below the 52-week high | it is 15.4% below its highest point of the past year | 15.4% |
| Since a 20-day breakout | it made a new 20-day high about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day low about 20 trading days ago | 20 sessions |
| All-time high | its highest closing price on record is $34.62 (set on 2013-07-12) | $34.62 |
| Given back of the 52-week move | over the past year its closes ranged ($17.21 to $24.24), and it has given back roughly a third of its rise from last year’s low — 42% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $19.67 to $19.90. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 42.1% |
| From the all-time high | it is 38.5% below its all-time high | -38.5% |
| Nearest price level | it is sitting right on a resistance level at $21.33 — a price it turned at 10 times since 2024-11-12, most recently on 2026-09-30. Since 2024-10-21 it has 8 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.2% |
| All-time low | its lowest closing price on record is $3.48 (set on 2008-11-21) | $3.48 |
| Above the all-time low | it is 511.3% above its all-time low | +511.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 30th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.493 between its high and its low — about 2.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.493 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $20.31 and $21.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $20.31 – $20.90 – $21.50 |
| Typical daily range (% of price) | its price moves about 2.3% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.3% |
| Stretch from the 200-day average | it is trading 1.0 daily range below its 200-day average price (2.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.0 daily range below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.53× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.1% |
|---|---|---|
| Gap filled | a 2.4% gap up opened on 2026-08-06 has been "filled" 51 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 51 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +2.41% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 0.3 percentage points (the stock gained 0.7% while the market gained 1.0%) | -0.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.6 percentage points (the stock gained 0.0% while the market gained 3.6%) | -3.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 19.5 percentage points (the stock lost 11.0% while the market gained 8.5%) | -19.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 9.1 percentage points (the stock gained 23.6% while the market gained 14.6%) | +9.1% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 2.7% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $21.76 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -2.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $20.89 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | +1.9% |
Price levels it has turned at before
INVA last closed at $21.28 on 2026-10-20. Since 2024-10-21 it has turned at 8 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $21.33 | Resistance | 0.2% above the last close | turned there 10 times · 2024-11-12 to 2026-09-30 |
| $21.88 | Resistance | 2.8% above the last close | turned there five times · 2025-06-16 to 2026-08-19 |
| $20.65 | Support | 3.0% below the last close | turned there three times · 2025-07-17 to 2026-08-31 |
| $20.25 | Support | 4.8% below the last close | turned there 9 times · 2024-10-28 to 2026-10-05 |
| $22.85 | Resistance | 7.4% above the last close | turned there twice · 2025-11-13 to 2026-05-26 |
| $19.43 | Support | 8.7% below the last close | turned there five times · 2024-11-25 to 2025-12-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $21.45.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 19 trading days, since 2026-09-24.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading above the 50-day moving average · trendless / choppy (low ADX) · lagging the market · Printed a doji candle · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$35.00 range $18.00 – $46.00
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for INVA
- Consensus EPS estimate$0.46 next reporting period, as of 2026-09-18
- Estimate change, 30 days$0.00 (0.0%) from $0.46, on 2026-08-12, 37-day window
- Readings revised upward0% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on royalty income from commercial partners and the success of their underlying pharmaceutical products.","Volatility in the valuation of equity investments impacting net income and financial results.","Risks related to the development, regulatory approval, and commercialization of new specialty pharmaceutical assets."]
What changed in the latest 10-Q
AI-assisted comparison of INVA's 10-Q filed 2026-08-05 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Notes:
- The newer filing text is truncated mid-sentence in the final paragraph ('...from a pure-play royalt'), and the older filing text is similarly truncated. The visible portions of the MD&A sections are effectively identical, so no factual changes can be identified from the provided excerpts.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for INVA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for INVA from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding INVA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 19,305,300
- Reported value $438,423,369
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about INVA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
INVA had 6,845,485 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
INVA had 9.48% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.66 days to cover at the same settlement.
- Reported short interest (shares) 6,845,485
- Short interest (% of shares outstanding) 9.48%
- Prior settlement (shares) 7,144,265
- Reported change -4.18%
- Days to cover (reported) 5.66
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- GlaxoSmithKline (GSK)
- AstraZeneca (AZN)
- Merck (MRK)
- Novartis (NVS)
- Sanofi (SNY)
- Gilead Sciences (GILD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare INVA vs…
INVA ranks in…
Frequently asked questions
What does INNOVIVA INC (INVA) do?
Innoviva is a holding company with a diversified portfolio of assets, including royalty interests in respiratory pharmaceutical products and a segment focused on the development and commercialization of infectious disease and other specialty medicines. The company actively manages its investments through various equity interests and direct operational holdings in pharmaceutical products.
What sector is INNOVIVA INC (INVA) in?
INNOVIVA INC (INVA) is classified in the Health Care sector. Its industry is Specialty Pharmaceuticals. It trades on NASDAQ.
Who are INNOVIVA INC's (INVA) competitors?
Notable peers of INNOVIVA INC (INVA) include GlaxoSmithKline, AstraZeneca, Merck, Novartis and Sanofi. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in INVA?
Yes — we hold 2 matched STOCK Act disclosures for INVA from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is INNOVIVA INC (INVA) overbought or oversold right now?
INNOVIVA INC (INVA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on INVA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.